Loading clinical trials...
Loading clinical trials...
This study is to test the feasibility and tolerability of the metoprolol optimal dosing pathway by observing the percentage of patients achieving target dose followed the pathway on ACS patients during hospitalization.
Acute coronary syndrome(ACS) is one of the main manifestations of cardiovascular disease and one of the main causes for hospitalization in adults. Previous studies showed that β-receptor blockers can reduce ACS patients' cardiovascular risk in both acute phase and secondary prevention. We summarized the metoprolol optimal dosing pathway based on Chinese and foreign guidelines as well as Chinese clinical practice. Primary endpoint is the percentage of patients achieving target dose at time of discharge. Secondary endpoints are the mean HR \& BP at discharge and during the follow up period of the Patients who have achieved target dose at discharge.
Age
18 - 80 years
Sex
ALL
Healthy Volunteers
No
The General Hospital of PLA
Beijing, China
Start Date
February 1, 2018
Primary Completion Date
July 30, 2019
Completion Date
July 30, 2020
Last Updated
July 19, 2019
1,000
ESTIMATED participants
Metoprolol
DRUG
Lead Sponsor
Yun Dai Chen
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions